2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $1.3B | $1.3B | $1.4B | $1.5B | $1.6B |
Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
Gross Profit | $1.3B | $1.3B | $1.4B | $1.5B | $1.6B |
Gross Profit % | 100% | 100% | 100% | 100% | 100% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $133M | $143M | -$2.6M | $45M | $103M |
Dep. & Amort. | $23M | $18M | $28M | $26M | $0 |
Def. Tax | $0 | $0 | $0 | $0 | $0 |
Stock Comp. | $6.7M | $8.4M | $8.9M | $9.5M | $9.9M |
Chg. in WC | $77M | $66M | $58M | $212M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $22M | $133M | $43M | $29M | $38M |
ST Investments | $6.7B | $6.6B | $5.5B | $523M | $5.4B |
Cash & ST Inv. | $6.7B | $6.7B | $5.5B | $29M | $5.4B |
Receivables | $0 | $0 | $0 | $0 | $0 |
Inventory | $0 | -$547M | -$795M | $0 | $0 |
Horace Mann reported record fourth-quarter core earnings of $1.62 per share, a 93% increase over the prior year, and full-year 2024 core EPS of $3.18, more than double 2023 earnings.
The company provided 2025 guidance for core EPS in the range of $3.6 to $3.9 per share and a double-digit return on equity, supported by continued profitability improvements and growth strategies.
Property and Casualty (P&C) profitability restoration efforts resulted in a full-year combined ratio of 97.9%, a 15.4-point improvement over the prior year, with further improvements expected in 2025.
Investments in technology, distribution, and product enhancements, including a next-generation cancer product and modernized P&C pricing processes, are expected to drive sustained profitable growth.
Catastrophe losses for 2025 are estimated at $90 million, reflecting exposure adjustments and mitigation efforts, while net investment income is projected between $370 million to $380 million, benefiting from higher interest rates.